An FDA advisory committee is scheduled next month to examine whether Bristol-Myers Squibb's saxagliptin and Novo Nordisk's liraglutide increase the risks of heart attack and stroke in patients with Type 2 diabetes. The move is in line with the agency's guidance issued in December.

Full Story:

Related Summaries